♦Cladribine



♦Cladribine





(kla’-drih-been)

Leustatin

Pregnancy Category D


Mechanism of Action

Unclear. A high intracellular concentration of cladribine is believed to inhibit ribonucleotide reductase, causing subsequent DNA strand breaks and inhibition of DNA synthesis and repair.


Indications

Hairy cell leukemia.


Metabolism/Excretion

Metabolized in the liver and excreted in the urine. Half-life: 5.4 hours.


Dosage Range

♦ Adult: 0.09 mg/kg per day for 7 consecutive days for a total dose of 0.63 mg/kg, or as a continuous 7-day infusion of the total 0.63-mg/kg dose.

♦ Pediatric: Safety and efficacy not established.


Drug Preparation/Stability

As a 24-hour infusion: Dilute the appropriate dose in 500 mL 0.9% sodium chloride. It is stable for 24 hours in a polyvinyl chloride bag at room temperature and ambient lighting. As a single continuous 7-day infusion: Withdraw the appropriate dose (7 × 0.09 mg/kg) from the individual vials using a 0.22-micron filter, and add to the infusion reservoir. Dilute with
bacteriostatic 0.9% sodium chloride containing benzyl alcohol preservative, drawn through a 0.22-micron syringe filter to a total volume of 100 mL. Do not use dextrose in water as a diluent because it accelerates the degradation of the drug. Stable for 7 days in the Pharmacia Deltec medication cassette.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 20, 2016 | Posted by in ONCOLOGY | Comments Off on ♦Cladribine

Full access? Get Clinical Tree

Get Clinical Tree app for offline access